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BACKGROUND: Sarcopenia is defined as a decrease in muscle mass accompanied by a decrease in muscle strength and performance. Sarcopenia arises 
from the disruption of the complex balance between anabolic 
and catabolic factors. Myostatin strongly influences muscle 
growth inhibition. Deletion and function loss of myostatin 
causes hyperplasia and skeletal muscle hypertrophy. 
METHODS: This study was an analytical cross-sectional 
study. Seventy respondents aged ≥60 years in Pedawa 
Village, Bali, Indonesia were selected by using the 
stratified random  sampling  technique.  Sarcopenia  status 
was  assessed  according  to  Asian  Working  Group  for 
Sarcopenia (AWGS) criteria, including muscle mass, grip 
strength, and walking speed. While the myostatin serum 
levels was measured by enzyme-linked immunosorbent 
assay (ELISA).
RESULTS: The incidence of sarcopenia in the elderly 
was 45 people (64.3%). Based on the analysis, there was a 
significant difference between myostatin levels in sarcopenia 
subjects (47.59 ng/mL) and non-sarcopenia subjects 
(39.7 ng/mL). Based on the statistical calculations, it was 
determined that the cut-off  range of myostatin levels was 
48.91 ng/mL. The prevalence ratio of sarcopenia incidence 
based on the myostatin levels in the elderly was 3.84, while 
based on the combination of age risk and myostatin levels 
was 9.75. 
CONCLUSION: Based of the data, there are significant 
differences of  myostatin level between elderly people with 
and without sarcopenia. The prevalence of high myostatin 
levels in elderly is almost 4 times higher than low myostatin 
levels in the elderly.
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Abstract
Introduction
In various countries, the increasing life expectancy in 
a sustainable manner has become one humanity's best 
achievements.(1,2) As a consequence, this also increases 
the proportion of elderly people. In 2010, there were an 
estimated 524 million world population aged 65 years or 
more, which is around 8% of the world's population.(1)
 Aging is related to the progressive change in 
physiological functions of all organs, which results in 
morbidity and mortality.(2,3) One of the important change 
that occurs in old age is a progressive decline in skeletal 
muscle mass, which in turn leads to sarcopenia, characterized 
by  decrease in muscle mass accompanied by a decrease in 
muscle strength and function. This causes disability in the 
elderly to even cause death.(4) The prevalence of sarcopenia 
increases with age, with the prevalence of sarcopenia at 
294
Print ISSN: 2085-3297, Online ISSN: 2355-9179The Indonesian Biomedical Journal, Vol.11, No.3, December 2019, p.225-337
age 65 to 70 years between 13% to 24% and more than 
50% at the age of more than 80 years.(5) Sarcopenia has 
implications for skeletal muscle performance, advanced 
physical and metabolic functions, thus posing a threat 
real in the health and economic fields. Sarcopenia is 
thought to arise due to various factors, namely changes in 
age-related hormones, steroids, sex, physical inactivity, 
and comorbid conditions such as heart failure, cancer, 
and diabetes.(6) Recent developments prove the striated 
muscle produces various cytokines and peptides known as 
myokine. Myokines as cytokines and peptides are produced, 
excreted, and released by muscles. Myokine appears as a 
challenge in the future as an attempt to identify biological 
mechanisms and determine therapeutic targets to prevent, 
delay, or cure the condition of sarcopenia. In the context 
of this molecular causation, growth and differentiation 
factor (GDF)8 or myostatin gets attention to be investigated 
regarding its function as a negative regulator of muscle.(6) 
Myostatin is part of the superfamily transforming growth 
factor-β. The amount is abundant in skeletal muscles, but 
is also found in lesser amounts in adipose tissue and heart 
muscle. Delivery of myostatin signals occurs via type IIB 
activin receptors (ActRIIB), which form a heterodimer 
with activin-like (ALK)4 or ALK5. Furthermore, the 
formation of  Sma and Mad (SMAD)4 occurs from SMAD2 
and SMAD3 phosphorylation with the heterodimer. The 
complex undergoes translocation to the nucleus and 
then functions in the proliferation and differentiation of 
skeletal muscle precursor cells, and the myofiber protein 
degradation pathway.(7-9) In addition, there is inhibition 
of action/mammary target of rapamycin (mTOR).(10) As 
a result of myostatin's activity in regulating cell growth, 
differentiation, and the pathways for delivering anabolic 
and catabolic signals, myostatin strongly influences muscle 
growth and post natal growth. Deletion and loss of function 
of myostatin causes skeletal muscle hyperplasia and 
hypertrophy.(6)
 Therefore the researchers intend to examine the 
relationship of myostatin with sarcopenia in elderly. The 
results of this study are expected to be a reference in future 
research to prevent and treat sarcopenia 
Methods
Research Design and Sample
This study was an analytical cross-sectional study The 
research was conducted in Pedawa Village, Buleleng 
Regency, Bali in April to October 2018. The sample used in 
this study were seventy elderly people with age more than 
or equal to 60 years old and chosen by stratified random 
sampling. The exclusion criteria from this study were 
patients with acute infection, malignancy, taking aspirin 
or  nonsteroidal anti-inflammatory drugs (NSAIDs) and 
corticosteroids for at least the last 2 weeks. 
 Data were collected by anthropometric measurements, 
muscle mass, grip strength, walking speed, and measurement 
of myostatin levels. Ethical permission was obtained from 
the Ethics Committee of the Research and Development 
Unit, Faculty of Medicine, Udayana University / Sanglah 
General Hospital with letter number: 1814/UN.14.2/
Litbang/201.
Anthropometry and Body Fat Percentage
Anthropometric measurements were carried out by 
measuring body weight and height. Measurement of height 
(cm) in the elderly based on knee height converted through 
the calculation of the Chumlea knee height formula.(11) The 
waist and hip circumference were measured in centimeters 
(cm), while the body mass index (BMI) was measured 
using  bioimpedance analysis (BIA), which then categorized 
into three groups, namely thin (BMI<18.5 kg/m2), normal 
(BMI=18.5-24.9 kg/m2), fat and obesity (BMI> 25 kg/m2). 
The percentage of body fat was measured by BIA.
Parameters of Sarcopenia
Based on the recommendations of the Asian Working Group 
for Sarcopenia (AWGS), the parameters of sarcopenia 
measured were muscle mass, grip strength, and walking 
speed.(12) Muscle mass measurements was done using BIA, 
which obtained skeletal muscle mass (upper limb muscle 
mass, lower limbs and trunk) with sceletal muscle index 
<7.0 kg/m2 in men and <5.7 kg/m2 in women classified as 
the low muscle mass. Grip strength examinations (muscle 
strength) were carried out with a handheld dynamometer, 
expressed in kilograms (kg) with grip strength <26 kg for 
men and <18 kg for women classified as low grip strength. 
The walking speed (m/s) was calculated by measuring 4.57 
meters walking speed with <0.8 m/s defined as a low walking 
speed. Meanwhile the sarcopenia status was classified into 
three group, namely pre-sarcopenia, sarcopenia and severe 
sarcopenia. Pre-sarcopenia was defined by the presence of 
low muscle mass without low grip strength and low walking 
speed, sarcopenia was defined by the presence of low 
muscle mass with one of low grip strength or low walking 
speed, and severe sarcopenia was defined by the presence 
three criteria, low muscle mass, low grip strength and low 
walking speed. 
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Myostatin Level
Myostatin levels were examined from blood serum. About 
5 mL of subject venous blood was taken by the researcher. 
This procedure was carried out by a professional who meets 
the requirements in the morning (8:00 to 10:00) to avoid 
the influence of changes in the circadian cycle. Myostatin 
levels were analyzed using the Quantikine HS Human 
Myostatin Immonoassay reagent (Catalogue #DGDF80, 
R&D Systems, Minneapolis, USA) measured by the 
enzyme-linked immunosorbent assay (ELISA) method with 
the units of pg/mL.
Data Analysis
Data analysis was done by using statistical tools SPSS 
version 16.0 (SPSS Inc, Chicago, USA). Descriptive 
statistical analysis was done to measure the central tendency 
(mean and median) and variability (range and standard 
devision). The independent t-test was applied to compare 
the myostatin levels among groups, with significancy level 
p<0.05. Calculation of prevalence ratio was done by using 
2x2 tables. 
Results
Variable Value p -value
Age (years) 69.40±8.31 0.001
Body Mass Index (kg/m2) 21.48±4.67 0.022
Body height based on knee height (cm) 161.57±6.37 0.200
Body weight (kg) 50.00±11.73 0.065
Hip circumference (cm) 86.58±13.56 0.000
Upper arm circumference 25.00±3.67 0.200
Body fat (%) 27.80±7.67 0.200
Visceral fat (%) 7.54±6.00 0.000
Total skeletal muscle mass (%) 90.15±14.21 0.085
     Upper leg muscle mass (%) 30.49±5.83 0.003
     Lower leg muscle mass (%) 39.15±6.09 0.001
     Trunk muscle mass (%) 19.10±3.72 0.200
Grip strength (kg) 19.24±6.83 0.027
Walking speed (m/s) 0.54±0.17 0.000
Myostatin (ng/mL) 42.33±1.52 0.200
Table 1. Characteristics of the research samples.
(27.1%) were classified as thin, 37 people (52.9%) were 
classified as normal, and 16 people (20%) were classified as 
obese. Table 1 illustrates the characteristics of the research 
sample.
Prevalence of Sarcopenia
The status of sarcopenia is known through sarcopenia 
parameters which were consisting of muscle mass, muscle 
strength and physical performance. From 70 samples, it 
was known that 47 people (67.1%) had low muscle mass, 
49 people (70%) had low muscle strength, and 65 people 
(92.9%) had low physical performance. Based on these 
parameters, the classification of sarcopenia status can be 
seen in Table 2.
 In sarcopenia group, there were more female (55.6%) 
than male (44.4%) while in the non sarcopenia group, 
there were more male (60%) than female (40%). In the 
sarcopenia group, 60% were ≥ 70 years old whereas in the 
non sarcopenia group there were more subjects under 70 
years old (64%). (Table 3).
Sarcopenia Status Frequency Percentage (%)
Normal 23 32.9
Pre-sarcopenia 2 2.9
Sarcopenia 9 12.9
Severe sarcopenia 36 51.4
Characteristics of The Research Sample
A total of 70 elderlies participated in this study. Male 
samples were 35 (50%), while female samples were 35 
(50%). Based on the BMI  value, as many as 19 people 
Table 2. Distribution of sarcopenia.
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Table 3. Distribution of sarcopenia based on gender and 
age group.
Sarcopenia 
(n=45)
Non-Sarcopenia 
(n=25)
Gender
    Male 20 (44.4%) 15 (60%)
    Female 25 (55.6%) 10 (40%)
Age
    <70 years old 18 (40%) 16 (64%)
    ≥70 years old 27 (60%) 9 (36%)
Characteristic
Sarcopenia Status 
Relationship between Myostatin and Sarcopenia 
Parameters
T-test was conducted to determine the difference in mean 
myostatin levels with sample characteristics, namely gender 
and age and sarcopenia parameters. Based on the analysis, 
it was found that there was a significant difference between 
myostatin levels in sarcopenia (47.59 ng/mL) and myostatin 
in non-sarcopenia (39.7 ng/mL) (p=0.037; 95% CI= -15.29 
- -049). The results of the average difference can be seen in 
Figure 1.
 Receiver operating characteristic (ROC) test was 
conducted to determine the cut off of the myostatin level 
range with a specificity of 80% and a sensitivity of 50%, 
which was 48.91 pg/mL. High level of myostatin (≥ 48.91 
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Figure 1. Mean difference of myostatin level with characteristics and parameters of sarcopenia.
pg/mL) was found higher in sarcopenia group compared to 
non-sarcopenia group. From these results the calculation 
of the ratio of the prevalence of sarcopenia according to 
myostatin levels in the elderly was 3.83 (Table 4). It means 
that high myostatin levels have a prevalence 3.83 times 
higher than low myostatin levels.
 The calculation of other sarcopenia risk factors, 
namely the age category and myostatin level was carried 
out to determine the effect of the combination of these risk 
factors. Based on the analysis, risk group was found higher 
in sarcopenia group compared to non-sarcopenia group. 
The ratio of the prevalence of sarcopenia based on age risk 
factors and myostatin levels was 9.75, that means subject 
with risks have higher prevalence of sarcopenia (Table 5).
Discussion
This study shows a considerable prevalence of sarcopenia 
of 64.3% (12.9% sarcopenia and 51.4% severe sarcopenia). 
This prevalence rate of this study is higher than other studies 
in Indonesia. A research in Bandung, Indonesia showed 
that the rate was 9.1%.(13) Research in the Asian region 
also found that the average prevalence of sarcopenia in the 
elderly was around 0.1% to 56.7%.(14) The magnitude of the 
sarcopenia prevalence rate in elderly age in Pedawa village, 
Bali illustrates the condition of the elderly population in 
populations isolated from outside environmental influences.
This study shows prevalence of sarcopenia is more higher 
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Sarcopenia Non- Sarcopenia
High 22 (81.5%) 5 (18.5%) 3.83 1.22-11.98
Low 23 (53.5%) 20 (46.5%)
Total 45 (64.3%) 25 (35.7%)
Level of 
Myostatin
Sarcopenia Status
PR* 95% CI**
Table 4. Analysis of the effect of myostatin levels on sarcopenia parameters.
*PR = Prevalence ratio;**CI = Confidence interval.
Sarcopenia Non-Sarcopenia
Risk 13 (92.9%) 1 (7.1%) 9.75 1.19-79.75
Non-risk 32 (57.1%) 24 (42.9%)
Total 45 (64.3%) 25 (35.7%)
Risks Based on 
Age Group and 
Myostatin Level
Sarcopenia Status
PR* 95% CI**
*PR = Prevalence ratio;**CI = Confidence interval.
Table 5. Analysis of the effect of risk based on age group and myostatin level on sarcopenia 
parameters.
prevalence of saropenia in women.(20) Another study using 
mice as the object of the study also showed a link between 
the absence of myostatin and a decrease in the incidence of 
sarcopenia.(21) Another study in old rats showed the role 
of anti-myostatin antibodies in increasing muscle mass and 
strength.(22) A cohort study in Taiwan with 1839 samples 
aged 53 to 92 years showed that in the elderly with low 
myostatin levels had higher risk of having a low skeletal 
muscle mass compared to the elderly with high myostatin 
levels (OR=3.23; 95% CI=1.49–7.01).(23) 
 In this study, the cut-off value of myostatin level is 
48.91 pg/mL. Based on it, 81.5% elderly with sarcopenia 
have myostatin level ≥48.91 pg/mL. A cohort study also 
showed the similar results that myostatin levels in low 
muscle mass (47.01 ng/pL) was higher than normal muscle 
mass (40.21 ng/pL) and myostatin levels at low physical 
performance (45.32 ng/pL) was higher compared to normal 
physical performance (37.73 ng/pL).(23) The influence 
of myostatin levels on the incidence of sarcopenia has a 
PR=3.83, which means that high levels of myostatin have 
a prevalence of sarcopenia almost 4 times higher than low 
levels of myostatin in the elderly. Whereas after calculating 
the combination of risk factors for age and myostatin levels, 
the prevalence ratio was 9.75. These results indicate an 
increase in the ratio of the prevalence of sarcopenia 2.5 
times compared to only having a risk of myostatin levels.
 Myostatin's performance on the incidence of 
sarcopenia through the myostatid-smad pathway inhibits 
in female (55.6%) than male. These results are similar with 
the research conducted in western China, whereas most 
female had sarcopenia compared to male by 12%.(15) This 
phenomenon can be caused by decreasing estrogen hormone 
in the elderly, especially at menopause which causes a 
decrease in bone density and muscle mass. This explains 
the role  of  hormones  as  a  risk  factor  for  sarcopenia.
(16) Insulin-like growth factor-1 (IGF-1) also decrease 
after menopause in elderly women. Estrogen and IGF-1 
are responsible for activating estrogen receptors. Estrogen 
receptors have an important role in muscle strength through 
the anabolic pathway and activating satellite cells. A 
decrease in estrogen and IGF-1 can cause elderly women 
loses muscle mass and muscle strength.(17)
 This study found 60% elderly in the sarcopenia group 
were ≥70 years old. Age affects the occurrence of sarcopenia. 
The prevalence of sarcopenia increases with age, even more 
than 40% of people aged 80 years experience sarcopenia.
(18) The aging process naturally affects muscle mass and 
muscle strength. Muscle mass and muscle strength decrease 
with age and muscle mass can decrease by 3% per year after 
age 60 years.(19) 
 Comparative analysis showed a significant mean 
difference of myostatin level between sarcopenia and 
non-sarcopenia group (p=0.037; 95% CI=-15.29 - -049). 
Other studies show similar results, where myostatin and 
sarcopenia are related. A study conducted previously 
showed that myostatin contributed to an increase in the 
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mTOR in response to growth supporting signals (such as 
insulin and IGF-1). Under normal circumstances, IGF-1 
and insulin stimulate protein synthesis through activation 
of the Akt/mTOR/P70s6k pathway and at the same time 
inhibit forkhead box O (FoxO) through phosphorylation. In 
pathological conditions, the phosphorylated does not inhibit 
FoxO so that FoxO accumulation occurs in the nucleus which 
then binds to DNA. The bond will induce transcription of 
E3 ubiquitin ligase.(24,25) through this pathway myostatin 
involvement in proliferation and differentiation of skeletal 
muscle precursor cells, and mature myofiber protein 
degradation pathways.(7-9)
Conclusion
The incidence of sarcopenia is more common in elderly 
women with more than 70 years of age. Based on the 
myostatin level, it was found that there were significant 
differences between the elderly with sarcopenia and the 
elderly without sarcopenia. Elderly people with  myostatin 
levels ≥48.91 pg/mL have a prevalence of sarcopenia almost 
4 times higher than elderly with myostatin levels <48.91 
pg/mL. Based on a combination of risk factors for age and 
myostatin levels there was an increase in the prevalence 
ratio of sarcopenia 2.5 times compared to only having a risk 
of myostatin levels. Myostatin can be considered for further 
investigation in an effort to be the target of sarcopenia 
preventive and curative therapy.
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